Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.

Trial Profile

The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms LIRA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
    • 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top